US Bancorp
LXRX icon

US Bancorp’s Lexicon Pharmaceuticals LXRX Stock Holding History

US Bancorp’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,082
Closed -$499 – 4264
2025
Q1 		$499 Sell
1,082
-542
-33% -$342 ﹤0.01% 4041
2024
Q4 		$1.2K Buy
+1,624
New +$1.96K ﹤0.01% 3939
2024
Q2 		– Sell
-1,200
Closed -$2.88K – 4052
2024
Q1 		$2.88K Buy
+1,200
New +$2.58K ﹤0.01% 3653
2018
Q4 		– Sell
-128
Closed -$1K – 3641
2018
Q3 		$1K Hold
128
– – ﹤0.01% 3574
2018
Q2 		$2K Buy
+128
New +$1.31K ﹤0.01% 3486
2017
Q4 		– Sell
-108
Closed -$1K – 3643
2017
Q3 		$1K Sell
108
-1,077
-91% -$15.9K ﹤0.01% 3497
2017
Q2 		$19K Buy
1,185
+1,021
+623% +$15.8K ﹤0.01% 2897
2017
Q1 		$2K Buy
164
+135
+466% +$2K ﹤0.01% 3400
2016
Q4 		$0 Buy
+29
New +$465 ﹤0.01% 3591

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's LXRX Position: Q2 2025 in Review

US Bancorp sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 1,082 shares — an estimated $499 sold.

US Bancorp first reported a position in LXRX in Q4 2016 and held it in 9 quarters. The position peaked at $19K in Q2 2017. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • US Bancorp reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • US Bancorp sold 1,082 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $499.
  • US Bancorp first reported a position in Lexicon Pharmaceuticals in Q4 2016 and held it in 9 quarters.
  • US Bancorp's Lexicon Pharmaceuticals position peaked at $19K in Q2 2017.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on US Bancorp's 13F filing for Q2 2025, filed 24 Jul 2025.